New Technologies
It is anticipated that the demand for new and existing vaccines will double by the year 2012. Sanofi Pasteur is continuously investing in state-of-the-art technologies to meet this growing demand.
The geographic diversity of our production facilities is a key strength for sanofi pasteur. The company has major production sites in France, the United States, Canada, China, Thailand and Argentina.
This diversification means an optimization of the production capacities to meet anticipated demands for current and new vaccines, through a variety of capital improvement programs. New technologies have the potential to play an important part in this expansion.
Sanofi Pasteur is investing in a number of leading-edge manufacturing approaches:
- Large scale, cell culture with immobilized cells on microcarriers or in suspension
- Large scale viral production involving different types of cell cultures
- Bacterial conjugate vaccine production involving conjugation precision process technology and performance purification technology
- Robust and reliable inactivation / detoxification technologies
- Combination vaccine production technology
- The ongoing upgrades to our manufacturing facilities assure our partners and our customers that sanofi pasteur can meet market demands for our products, with respect to environmental concerns.
Access to categories:
